Sunday, September 22, 2019

Kymab appoint industry veteran as new CEO

Kymab, a UK biopharma developing antibody-based therapeutics, has appointed Simon Sturge as its new CEO.

He succeeds David Chiswell, who remains a scientific adviser to the company.

“We are delighted that such an experienced leader as Simon will lead Kymab to its next stage of growth,” said Martin Nicklasson, Non-Executive Chair.

He added: “This appointment is part of Kymab’s strategy to position itself for long-term success, building on the incredibly strong R&D foundation of the company.”

Mr Sturge joins Kymab from Merck KGaA, where he was Executive Vice President Global Strategy, Business Development & Global Operations.

Previously, he was Chief Operating Officer of Merck Healthcare, responsible for company’s global commercial and manufacturing operations.

Prior to joining Merck KGaA, he served as Corporate Senior Vice President, Biopharmaceuticals at Boehringer Ingelheim, where he had responsibility for the research, development and commercialisation of the company’s global biosimilar portfolio.

Before that, he held CEO roles at a number of healthcare companies including Celltech Biologics, and he served as founder and CEO of Ribotargets, which was acquired by British Biotech and subsequently renamed Vernalis.

News

Roche gains breakthrough status with Gazyva for lupus nephritis

Roche gains breakthrough status with Gazyva for lupus nephritis

The FDA has granted Breakthrough Therapy Designation to Roche’s Gazyva (obinutuzumab) for adults with lupus nephritis. Lupus nephritis is a potentially life-threatening manifestation of systemic...
CASI Pharmaceuticals names new president

CASI Pharmaceuticals names new president

Larry Zhang has been promoted to President at US biopharma, CASI Pharmaceuticals. Mr Zhang joined the company in September 2018 as President of its Chinese...
Versantis raises funds to advance development of liver disease therapy

Versantis raises funds to advance development of liver disease therapy

Versantis, a Swiss-based clinical-stage biotech company developing disruptive therapies for rare liver and paediatric diseases, has closed a CHF 16 million Series B financing...